MPR News reports on efforts to tighten protections for genetic testing customers.
During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.
23andMe and GlaxoSmithKline's partnership has uncovered half a dozen drug targets but also raised ethical questions, the Wall Street Journal reports.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.
CNBC reports that 23andMe is piloting a new program to incorporate customers' medical histories and lab tests with their genetic data.
The San Diego-based firm said it expects second quarter revenues of $835 million, short of the average analyst estimate of $888 million.
Bloomberg reports that some of genetic testing firm Vitagene's records were exposed online, including ones containing genetic information.
Slate's Jane Hu compares some at-home genetic tests to astrology.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.